推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 升華拜克近日發(fā)布公告稱，升華拜克2016年實(shí)現(xiàn)營業(yè)收入1,005,491,316.01元，同比下降0.46%；營業(yè)利潤234,419,613.11元，同比增長84.19%；利潤總額235,335,764.98元，同比增長74.75%；實(shí)現(xiàn)歸屬上市公司股東凈利潤235,610,584.02元，同比增長68.43%。
公告稱，營業(yè)利潤、利潤總額、實(shí)現(xiàn)歸屬上市公司股東凈利潤同比大幅增長主要系公司聯(lián)營企業(yè)財(cái)通基金管理有限公司(以下簡稱“財(cái)通基金”)和青島易邦生物工程有限公司(以下簡稱“青島易邦”)本期利潤增加，以及公司通過浙江昆侖創(chuàng)元股權(quán)投資合伙企業(yè)(有限合伙)參與投資的華鑫信托-方正電機(jī)及中國物流有限公司股權(quán)投資項(xiàng)目于2016年度收回投資本金及收益所致。其中，財(cái)通基金資產(chǎn)管理規(guī)模同比上升,青島易邦繼續(xù)加強(qiáng)高端產(chǎn)品市場推廣，財(cái)通基金與青島易邦2016年度實(shí)現(xiàn)的凈利潤均同比增加。
此前，其發(fā)布的2016年年中報(bào)告顯示，阿維菌素市場需求不及預(yù)期，銷售收入1622.68萬元，同比下降72.36%。2016年4月升華拜克發(fā)布《未來發(fā)展戰(zhàn)略規(guī)劃(2016-2020年)》，表明將泛娛樂作為公司未來的戰(zhàn)略重點(diǎn)。目前發(fā)行股份及支付現(xiàn)金購買資產(chǎn)并募集配套資金的方案在持續(xù)推進(jìn)。
